- Home
- RYTM vs ALRM Comparison
RYTM vs ALRM Comparison
Compare RYTM & ALRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- ALRM
- Stock Information
- Founded
- RYTM 2008
- ALRM 2000
- Country
- RYTM United States
- ALRM United States
- Employees
- RYTM N/A
- ALRM N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- ALRM Computer Software: Prepackaged Software
- Sector
- RYTM Health Care
- ALRM Technology
- Exchange
- RYTM Nasdaq
- ALRM Nasdaq
- Market Cap
- RYTM 3.1B
- ALRM 2.7B
- IPO Year
- RYTM 2017
- ALRM 2015
- Fundamental
- Price
- RYTM $56.12
- ALRM $62.95
- Analyst Decision
- RYTM Strong Buy
- ALRM Buy
- Analyst Count
- RYTM 10
- ALRM 6
- Target Price
- RYTM $65.80
- ALRM $65.33
- AVG Volume (30 Days)
- RYTM 552.7K
- ALRM 483.2K
- Earning Date
- RYTM 11-05-2024
- ALRM 02-20-2025
- Dividend Yield
- RYTM N/A
- ALRM N/A
- EPS Growth
- RYTM N/A
- ALRM 80.16
- EPS
- RYTM N/A
- ALRM 2.31
- Revenue
- RYTM $112,530,000.00
- ALRM $923,824,000.00
- Revenue This Year
- RYTM $63.64
- ALRM $8.17
- Revenue Next Year
- RYTM $42.98
- ALRM $4.58
- P/E Ratio
- RYTM N/A
- ALRM $27.20
- Revenue Growth
- RYTM 81.55
- ALRM 6.98
- 52 Week Low
- RYTM $35.17
- ALRM $51.87
- 52 Week High
- RYTM $68.58
- ALRM $77.29
- Technical
- Relative Strength Index (RSI)
- RYTM 46.95
- ALRM 44.36
- Support Level
- RYTM $53.39
- ALRM $65.90
- Resistance Level
- RYTM $57.27
- ALRM $68.54
- Average True Range (ATR)
- RYTM 2.32
- ALRM 1.82
- MACD
- RYTM -0.55
- ALRM -0.80
- Stochastic Oscillator
- RYTM 33.21
- ALRM 6.08
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About ALRM Alarm.com Holdings Inc.
Alarm.com Holdings Inc has two reportable segments: Alarm.com & Other. The Alarm.com segment represents the cloud-based Software platforms for intelligently connected property & related solutions. The other segment is focused on researching, developing & offering residential & commercial automation solutions & energy management products & services in adjacent markets. The majority of revenue is from the Alarm.com segment. The platform allows home & business owners to secure their properties and automate & control an array of connected devices. SaaS & license fees from service providers, who resell these services & pay Alarm.com a monthly subscription, are the sources of revenue for the firm. The majority of revenue is generated in the United States & Canada.